• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Recent advances in uncovering the mechanisms contributing to BIRD-2-induced cell death in B-cell cancer cells.

作者信息

Kerkhofs Martijn, Vervloessem Tamara, Bittremieux Mart, Bultynck Geert

机构信息

KU Leuven, Laboratory of Molecular and Cellular Signaling, Department of Cellular and Molecular Medicine and Leuven Kanker Instituut (LKI), Campus Gasthuisberg ON-I Bus 802, Leuven, Belgium.

出版信息

Cell Death Dis. 2019 Jan 17;10(2):42. doi: 10.1038/s41419-018-1297-z.

DOI:10.1038/s41419-018-1297-z
PMID:30718472
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6361978/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2317/6361978/ccbcaff2cb6e/41419_2018_1297_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2317/6361978/ccbcaff2cb6e/41419_2018_1297_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2317/6361978/ccbcaff2cb6e/41419_2018_1297_Fig1_HTML.jpg

相似文献

1
Recent advances in uncovering the mechanisms contributing to BIRD-2-induced cell death in B-cell cancer cells.揭示B细胞癌细胞中BIRD-2诱导细胞死亡机制的最新进展。
Cell Death Dis. 2019 Jan 17;10(2):42. doi: 10.1038/s41419-018-1297-z.
2
CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20 (+), surface CD20 (-).具有不寻常表型的CD5阳性弥漫性大B细胞淋巴瘤：细胞质CD20阳性(+)，表面CD20阴性(-)。
Leuk Lymphoma. 2006 Jul;47(7):1415-7. doi: 10.1080/10428190600581625.
3
Follicular origin of a subset of CD5(+) diffuse large B-cell lymphomas.CD5(+)弥漫性大B细胞淋巴瘤子集的滤泡起源
Am J Clin Pathol. 2006 Jun;125(6):954-5.
4
[Unclassified B-cell lymphomas with "grey zone" characteristics].具有“灰色地带”特征的未分类B细胞淋巴瘤
Zhonghua Bing Li Xue Za Zhi. 2011 Apr;40(4):278-81.
5
Rituximab for early-stage diffuse large-B-cell lymphoma.利妥昔单抗用于早期弥漫性大B细胞淋巴瘤
Lancet Oncol. 2006 May;7(5):357-9. doi: 10.1016/S1470-2045(06)70668-4.
6
BIRD-2, a BH4-domain-targeting peptide of Bcl-2, provokes Bax/Bak-independent cell death in B-cell cancers through mitochondrial Ca-dependent mPTP opening.BIRD-2，一种 Bcl-2 的 BH4 结构域靶向肽，通过线粒体钙依赖性 mPTP 开放诱导 B 细胞癌中 Bax/Bak 非依赖性细胞死亡。
Cell Calcium. 2021 Mar;94:102333. doi: 10.1016/j.ceca.2020.102333. Epub 2021 Jan 12.
7
Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma.细胞周期蛋白D3是弥漫性大B细胞淋巴瘤的一个预测和预后因素。
Clin Cancer Res. 2002 Mar;8(3):729-33.
8
[Histological and immunohistochemical characteristics of diffuse large cell B-cell lymphomas].[弥漫性大细胞B细胞淋巴瘤的组织学和免疫组化特征]
Arkh Patol. 2000 Nov-Dec;62(6):19-24.
9
Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype.具有浆细胞分化的侵袭性大 B 细胞淋巴瘤：浆母细胞淋巴瘤和具有部分浆母细胞表型的弥漫性大 B 细胞淋巴瘤的免疫组织化学特征。
Haematologica. 2010 Aug;95(8):1342-9. doi: 10.3324/haematol.2009.016113. Epub 2010 Apr 23.
10
Anti-angiogenesis and diffuse large B-cell lymphoma: a new treatment opportunity?抗血管生成与弥漫性大B细胞淋巴瘤：一个新的治疗机遇？
Leuk Lymphoma. 2006 Jun;47(6):961-2. doi: 10.1080/10428190600593125.

引用本文的文献

1
Bcl-xL acts as an inhibitor of IPR channels, thereby antagonizing Ca-driven apoptosis.Bcl-xL 作为 IPR 通道的抑制剂，从而拮抗 Ca 驱动的细胞凋亡。
Cell Death Differ. 2022 Apr;29(4):788-805. doi: 10.1038/s41418-021-00894-w. Epub 2021 Nov 8.
2
Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma.内质网应激与氧化应激之间的相互作用：多发性骨髓瘤中的动态组合。
Cell Mol Life Sci. 2021 Apr;78(8):3883-3906. doi: 10.1007/s00018-021-03756-3. Epub 2021 Feb 18.
3
DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition.

本文引用的文献

1
Creating a New Cancer Therapeutic Agent by Targeting the Interaction between Bcl-2 and IP Receptors.通过靶向 Bcl-2 和 IP 受体相互作用来创建新型癌症治疗剂。
Cold Spring Harb Perspect Biol. 2019 Sep 3;11(9):a035196. doi: 10.1101/cshperspect.a035196.
2
Extracellular and ER-stored Ca contribute to BIRD-2-induced cell death in diffuse large B-cell lymphoma cells.细胞外和内质网储存的钙有助于BIRD-2诱导弥漫性大B细胞淋巴瘤细胞死亡。
Cell Death Discov. 2018 Nov 2;4:101. doi: 10.1038/s41420-018-0118-6. eCollection 2018.
3
Targeting Bcl-2-IP receptor interaction to treat cancer: A novel approach inspired by nearly a century treating cancer with adrenal corticosteroid hormones.
获得 Venetoclax 耐药性的 DLBCL 细胞对 BIRD-2 无敏感性，但可通过 Bcl-XL 抑制重新对 Venetoclax 敏感。
Biomolecules. 2020 Jul 21;10(7):1081. doi: 10.3390/biom10071081.
4
Partners in Crime: Towards New Ways of Targeting Calcium Channels.共犯：探索靶向钙通道的新方法
Int J Mol Sci. 2019 Dec 16;20(24):6344. doi: 10.3390/ijms20246344.
5
Bcl-2-Protein Family as Modulators of IP Receptors and Other Organellar Ca Channels.Bcl-2 蛋白家族作为 IP 受体和其他细胞器钙通道的调节剂。
Cold Spring Harb Perspect Biol. 2020 Apr 1;12(4):a035089. doi: 10.1101/cshperspect.a035089.
6
Creating a New Cancer Therapeutic Agent by Targeting the Interaction between Bcl-2 and IP Receptors.通过靶向 Bcl-2 和 IP 受体相互作用来创建新型癌症治疗剂。
Cold Spring Harb Perspect Biol. 2019 Sep 3;11(9):a035196. doi: 10.1101/cshperspect.a035196.
靶向 Bcl-2-IP 受体相互作用治疗癌症：一种受近一个世纪使用肾上腺皮质激素治疗癌症启发的新方法。
Biochim Biophys Acta Mol Cell Res. 2018 Nov;1865(11 Pt B):1795-1804. doi: 10.1016/j.bbamcr.2018.07.020. Epub 2018 Jul 25.
4
Constitutive IP signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP receptor disruptor BIRD-2.组成型 IP 信号是 B 细胞癌对 Bcl-2/IP 受体破坏剂 BIRD-2 敏感的基础。
Cell Death Differ. 2019 Mar;26(3):531-547. doi: 10.1038/s41418-018-0142-3. Epub 2018 Jun 13.
5
Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax.弥漫性大B细胞淋巴瘤细胞对Bcl-2抑制剂BIRD-2与维奈克拉的相互敏感性。
Oncotarget. 2017 Dec 4;8(67):111656-111671. doi: 10.18632/oncotarget.22898. eCollection 2017 Dec 19.
6
TAT‑fused IP3R‑derived peptide enhances cisplatin sensitivity of ovarian cancer cells by increasing ER Ca2+ release.TAT 融合的 IP3R 衍生肽通过增加内质网 Ca2+释放增强卵巢癌细胞对顺铂的敏感性。
Int J Mol Med. 2018 Feb;41(2):809-817. doi: 10.3892/ijmm.2017.3260. Epub 2017 Nov 16.
7
Why do BCL-2 inhibitors work and where should we use them in the clinic?BCL-2 抑制剂为何有效，以及我们应在临床何处使用它们？
Cell Death Differ. 2018 Jan;25(1):56-64. doi: 10.1038/cdd.2017.183. Epub 2017 Oct 27.
8
A BH3 Mimetic for Killing Cancer Cells.一种用于杀死癌细胞的 BH3 模拟物。
Cell. 2016 Jun 16;165(7):1560. doi: 10.1016/j.cell.2016.05.080.
9
Bcl-2 proteins and calcium signaling: complexity beneath the surface.Bcl-2蛋白与钙信号传导：表面之下的复杂性
Oncogene. 2016 Sep 29;35(39):5079-92. doi: 10.1038/onc.2016.31. Epub 2016 Mar 14.
10
A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.一种靶向Bcl-2的BH4结构域的合成肽单独或与靶向Bcl-2的BH3结合口袋的药物联合使用时，可诱导多发性骨髓瘤和滤泡性淋巴瘤细胞凋亡。
Oncotarget. 2015 Sep 29;6(29):27388-402. doi: 10.18632/oncotarget.4489.